enicepatide vs Semaglutide (Wegovy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
enicepatide
Developed by Roche and partners
NCT06525935 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
Reported efficacy
Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)
Result source: NCT06525935
Semaglutide (Wegovy)
Marketed by Novo Nordisk
NCT03548935 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.
Next expected readout: December 2026 · NCT05173714 (registry estimate)
Reported efficacy
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)
Result source: NCT03574597
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | enicepatide | Semaglutide (Wegovy) |
|---|---|---|
| Body weight, % change | —Trial running · NCT07670416 | -19.5% vs -3.8%−15.7 vs placeboNCT0564670628 other results
|
| Weight loss of 5% or more | —Trial running · NCT07670416 | 87% vs 29.2%+57.8 vs placeboNCT050647351 other result
|
| Weight loss of 10% or more | —Trial running · NCT07670416 | 70.4% vs 9.2%+61.2 vs placeboNCT050647359 other results
|
| Waist circumference, change (cm) | —Trial running · NCT07670416 | -7.5 vs -1−6.5 vs placeboNCT0357459735 other results
|
Body weight, % change
- enicepatide
- —Trial running · NCT07670416
- Semaglutide (Wegovy)
- -19.5% vs -3.8%−15.7 vs placeboNCT05646706
28 other results
- -14.2% vs -2.5% NCT05064735
- -13.4% vs -1.9% NCT03811574
- -14.4% vs -2.7% NCT05040971
- -13.9% vs -2.5% NCT04788511
- -12.2% vs -2.2% NCT06041217
- -12.5% vs -3.6% NCT04251156
- -9.9% vs -1.9% NCT03811574
- -16.4% vs -2.6% NCT04998136
- -16.4% vs -2.7% NCT04998136
- -16.4% vs -6.4% NCT04074161
- -9.4% vs -0.9% NCT03574597
- -17.7% vs -5.4% NCT03548987
- -7.8% vs -6% NCT03611582
- -14.8% vs 2.3% NCT04102189
- -16.4% vs -1.6% NCT04074161
- -15.8% vs -3.3% NCT03693430
- -9.9% vs -7.2% NCT03552757
- -19.5% vs -16.4% NCT05646706
- -5.5% vs -3.1% NCT04969939
- -13.8% vs -2.3% NCT02453711
- -16.3% vs -2.3% NCT02453711
- -11.2% vs -2.3% NCT02453711
- -11.4% vs -2.3% NCT02453711
- -11.6% vs -2.3% NCT02453711
- -8.6% vs -2.3% NCT02453711
- -6.0% vs -2.3% NCT02453711
- -4.5% vs -0.2% NCT04779697
- -13.6% vs -7.4% NCT05579249
Weight loss of 5% or more
- enicepatide
- —Trial running · NCT07670416
- Semaglutide (Wegovy)
- 87% vs 29.2%+57.8 vs placeboNCT05064735
1 other result
- 72.5% vs 17.7% NCT04102189
Weight loss of 10% or more
- enicepatide
- —Trial running · NCT07670416
- Semaglutide (Wegovy)
- 70.4% vs 9.2%+61.2 vs placeboNCT05064735
9 other results
- 61.8% vs 8.1% NCT04102189
- 65.9% vs 9.5% NCT04788511
- 64.6% vs 10.1% NCT02453711
- 71.9% vs 10.1% NCT02453711
- 57.8% vs 10.1% NCT02453711
- 58.5% vs 10.1% NCT02453711
- 56.0% vs 10.1% NCT02453711
- 36.6% vs 10.1% NCT02453711
- 18.9% vs 10.1% NCT02453711
Waist circumference, change (cm)
- enicepatide
- —Trial running · NCT07670416
- Semaglutide (Wegovy)
- -7.5 vs -1−6.5 vs placeboNCT03574597
35 other results
- -14.1 vs -4.4 NCT03548935
- -6.9 vs 3.2 NCT03548987
- -15.2 vs -4.3 NCT03693430
- -9.7 vs -4.3 NCT03552757
- -15.2 vs -6.1 NCT03611582
- -18 vs -5.6 NCT05646706
- -13.3 vs -5.9 NCT05064735
- -12.7 vs -0.5 NCT04102189
- -13.6 vs -2 NCT04074161
- -11.2 vs -1.8 NCT03811574
- -10.2 vs -1.9 NCT03811574
- -11.6 vs -2.8 NCT05040971
- -12 vs -2.8 NCT04788511
- -14.3 vs -4.5 NCT03693430
- -9.1 vs -2.4 NCT06041217
- -11.1 vs -3.8 NCT04251156
- -7.8 vs -1.8 NCT03811574
- -7.6 vs -1.9 NCT03811574
- -12 vs -3 NCT04998136
- -4.8 vs -2.7 NCT04969939
- -12.3 vs -3.5 NCT02453711
- -14.9 vs -3.5 NCT02453711
- -10.9 vs -3.5 NCT02453711
- -11.1 vs -3.5 NCT02453711
- -11.0 vs -3.5 NCT02453711
- -8.8 vs -3.5 NCT02453711
- -6.1 vs -3.5 NCT02453711
- -18.2 vs -14.7 NCT05616013
- -21.3 vs -14.7 NCT05616013
- -15.8 vs -13.6 NCT05616013
- -19.0 vs -13.6 NCT05616013
- -15.6 vs -14.7 NCT05616013
- -18.1 vs -14.7 NCT05616013
- -14.6 vs -13.6 NCT05616013
- -16.6 vs -13.6 NCT05616013
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. enicepatide: 0 of 4 rows · Semaglutide (Wegovy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Wegovy) |
|---|---|
| Dropout rate | —2.4 mg weeklya NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results5.1%2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 11%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 3.2%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 2.9% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 16.7%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 15.3%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 14.4%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 0%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 4.6%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 0% NCT04998136 · Phase 3 · registry result, not featured evidence 9.2%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 7.2%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 2.7%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 1.5%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 4.8%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 2.6%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 2%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 2%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 33.9%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 38.6%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 50%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 37.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5% NCT05302596 · Phase 2 · registry result, not featured evidence 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.9%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 8.7%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.9%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.7%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 10.4% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —2.4 mg weeklya NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 5.3%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 — NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 6.4%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 —Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination —Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence —2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence — NCT04998136 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence —2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence —2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence —1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 1.8%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.3%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 5.4%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 — NCT05302596 · Phase 2 · registry result, not featured evidence —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination —0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence —0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence —0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence — NCT04779697 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 9.8%2.4 mg weeklya NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 40 more results—2.4 mg weekly NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 —2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 7.7%2.4 mg NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 9.9%2.4 mg NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 33.4% NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 9.1%2.4 mg NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 4.2%Behavioral Treatment + Medication NCT05548647 · Phase 4 · registry result, not featured evidence · combination 0%Continued Medication (Semaglutide) NCT05548647 · Phase 4 · registry result, not featured evidence 1.2%2.4 mg NCT05579249 · Phase 4 · registry result, not featured evidence 8.1%2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence —2.4 mg NCT06041217 · Phase 3 · registry result, not featured evidence 7.3%7.2 mg NCT05646706 · Phase 3 · registry result, not featured evidence 12.9% NCT04998136 · Phase 3 · registry result, not featured evidence 10%2.4 mg NCT05064735 · Phase 3 · registry result, not featured evidence 8.7%2.4 mg NCT05040971 · Phase 3 · registry result, not featured evidence 13.3%2.4 mg NCT04788511 · Phase 3 · registry result, not featured evidence 5.6%2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence —2.4 mg NCT04251156 · Phase 3 · registry result, not featured evidence 11.3%2.4 mg NCT04102189 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT04074161 · Phase 3 · registry result, not featured evidence 7.9%2.4 mg NCT03693430 · Phase 3 · registry result, not featured evidence 5%2.4 mg NCT03811574 · Phase 3 · registry result, not featured evidence 7%1.7 mg NCT03811574 · Phase 3 · registry result, not featured evidence 10.7%30 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.7%30 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 12.5%10 mg/kg + 1.0 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 14.5%10 mg/kg + 2.4 mg NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 0% NCT05302596 · Phase 2 · registry result, not featured evidence 12.5%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%2.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 4.3%1.0 mg + 2.4 mg NCT04969939 · Phase 2 · registry result, not featured evidence · combination 12.7%0.4 mg NCT02453711 · Phase 2 · registry result, not featured evidence 6.8%0.4 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 5.8%0.3 mg NCT02453711 · Phase 2 · registry result, not featured evidence 5.9%0.3 mg (Fast Escalation) NCT02453711 · Phase 2 · registry result, not featured evidence 4.9%0.2 mg NCT02453711 · Phase 2 · registry result, not featured evidence 7.8%0.1 mg NCT02453711 · Phase 2 · registry result, not featured evidence 12.6%0.05 mg NCT02453711 · Phase 2 · registry result, not featured evidence 2.1% NCT04779697 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 2.4 mg weeklya nausea 44.1% (placebo 17.4%) diarrhoea 31.5% (placebo 15.9%) vomiting 24.6% (placebo 6.6%) NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results2.4 mg diarrhoea 14.4% (placebo 7.1%) nausea 14% (placebo 4.9%) constipation 11.6% (placebo 6%) NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 33.5% (placebo 9.2%) diarrhoea 21.3% (placebo 11.9%) vomiting 21.3% (placebo 2.7%) NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 covid-19 20.3% (placebo 20.3%) nausea 18.1% (placebo 3.8%) diarrhoea 10.6% (placebo 4%) NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3 2.4 mg nausea 58.2% (placebo 22.1%) constipation 36.9% (placebo 24.5%) diarrhoea 36.1% (placebo 22.1%) NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 nausea 73.6% (placebo 25%) constipation 52.8% (placebo 16.7%) diarrhea 37.5% (placebo 22.9%) NCT05548647 · Phase 4 · registry result, not featured evidence · combination diarrhea 20% (placebo 22.9%) constipation 10% (placebo 16.7%) eructation 10% (placebo 6.3%) NCT05548647 · Phase 4 · registry result, not featured evidence 2.4 mg decreased appetite 19.3% (placebo 2.5%) diarrhoea 18.6% (placebo 7.4%) nausea 18% (placebo 2.5%) NCT06041217 · Phase 3 · registry result, not featured evidence 7.2 mg nausea 43.7% (placebo 13.4%) diarrhoea 27.3% (placebo 12.9%) vomiting 24.8% (placebo 7%) NCT05646706 · Phase 3 · registry result, not featured evidence nausea 37.6% (placebo 14.3%) diarrhoea 27.7% (placebo 6.1%) constipation 21.8% (placebo 16.3%) NCT04998136 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 21.9% (placebo 8.9%) covid-19 18.6% (placebo 22.2%) constipation 11.9% (placebo 5.2%) NCT05064735 · Phase 3 · registry result, not featured evidence 2.4 mg covid-19 34.8% (placebo 30.4%) nausea 29% (placebo 4.3%) constipation 18.1% (placebo 0%) NCT05040971 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 17.1% (placebo 2.6%) covid-19 13.7% (placebo 15.4%) diarrhoea 9.1% (placebo 3.8%) NCT04788511 · Phase 3 · registry result, not featured evidence 2.4 mg diarrhoea 26.1% (placebo 10.3%) nausea 24.1% (placebo 7.1%) upper respiratory tract infection 20.5% (placebo 20.6%) NCT04251156 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 42.1% (placebo 17.9%) vomiting 36.1% (placebo 10.4%) diarrhoea 21.8% (placebo 19.4%) NCT04102189 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 61.1% (placebo 22.4%) constipation 38.9% (placebo 23.5%) diarrhoea 27.8% (placebo 25.9%) NCT04074161 · Phase 3 · registry result, not featured evidence 2.4 mg nausea 53.3% (placebo 21.7%) diarrhoea 34.9% (placebo 23.7%) constipation 30.9% (placebo 11.2%) NCT03693430 · Phase 3 · registry result, not featured evidence 2.4 mg nasopharyngitis 26.6% (placebo 17.8%) constipation 26.1% (placebo 3%) nausea 17.6% (placebo 4%) NCT03811574 · Phase 3 · registry result, not featured evidence 1.7 mg nasopharyngitis 24% (placebo 17.8%) diarrhoea 22% (placebo 5.9%) constipation 19% (placebo 3%) NCT03811574 · Phase 3 · registry result, not featured evidence 30 mg/kg + 1.0 mg muscle spasms 64.3% acne 55.4% diarrhoea 44.6% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 30 mg/kg + 2.4 mg muscle spasms 63.6% acne 52.7% diarrhoea 49.1% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 1.0 mg muscle spasms 57.1% diarrhoea 48.2% acne 42.9% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 10 mg/kg + 2.4 mg muscle spasms 65.5% nausea 61.8% diarrhoea 52.7% NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2 gastrointestinal side effects: constipation 57.1% gi side effects: nausea 28.6% gi side effects: vomiting 14.3% NCT05302596 · Phase 2 · registry result, not featured evidence 2.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 87.5% (placebo 12.5%) vomiting 75% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 2.0 mg + 2.4 mg nausea 62.5% (placebo 12.5%) constipation 50% (placebo 0%) vomiting 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg decreased appetite 87.5% (placebo 75%) nausea 50% (placebo 12.5%) abdominal pain 37.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 1.0 mg + 2.4 mg nausea 44.7% (placebo 12.5%) vomiting 31.9% (placebo 0%) constipation 25.5% (placebo 0%) NCT04969939 · Phase 2 · registry result, not featured evidence · combination 0.4 mg nausea 48% (placebo 17.6%) diarrhoea 37.3% (placebo 11.8%) constipation 23.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.4 mg (Fast Escalation) nausea 48.5% (placebo 17.6%) constipation 28.2% (placebo 4.4%) diarrhoea 27.2% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg nausea 41.7% (placebo 17.6%) diarrhoea 26.2% (placebo 11.8%) constipation 17.5% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.3 mg (Fast Escalation) nausea 53.9% (placebo 17.6%) diarrhoea 27.5% (placebo 11.8%) vomiting 20.6% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.2 mg nausea 43.7% (placebo 17.6%) diarrhoea 34% (placebo 11.8%) constipation 25.2% (placebo 4.4%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.1 mg nausea 41.2% (placebo 17.6%) diarrhoea 24.5% (placebo 11.8%) nasopharyngitis 22.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence 0.05 mg nausea 31.1% (placebo 17.6%) diarrhoea 19.4% (placebo 11.8%) nasopharyngitis 15.5% (placebo 11.8%) NCT02453711 · Phase 2 · registry result, not featured evidence nausea 58.3% (placebo 20.8%) abdominal pain 31.3% (placebo 20.8%) diarrhea 29.2% (placebo 10.4%) NCT04779697 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 30 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Wegovy)
show 3 more results
show 3 more results
show 14 more results
show 13 more results
show 13 more results
show 35 more results
show 22 more results
show 2 more results
+ 146 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · Semaglutide (Wegovy)'s landscape